K
Kensuke Naito
Researcher at Hamamatsu University School of Medicine
Publications - 52
Citations - 1741
Kensuke Naito is an academic researcher from Hamamatsu University School of Medicine. The author has contributed to research in topics: Acute promyelocytic leukemia & Leukemia. The author has an hindex of 20, co-authored 49 publications receiving 1661 citations. Previous affiliations of Kensuke Naito include Nagoya University & Hamamatsu University.
Papers
More filters
Journal ArticleDOI
Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia
Kazunori Ohnishi,Hitoshi Yoshida,Kazuyuki Shigeno,Satoki Nakamura,Shinya Fujisawa,Kensuke Naito,Kaori Shinjo,Yota Fujita,Hirotaka Matsui,Akihiro Takeshita,Shiho Sugiyama,Hiroshi Satoh,Hajime Terada,Ryuzo Ohno +13 more
TL;DR: Eight patients with acute promyelocytic leukemia who had relapse after extensive previous therapy with all-trans retinoic acid and chemotherapy, including anthracycline were treated with arsenic trioxide to treat them and five patients achieved complete remission.
Journal ArticleDOI
Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
Jin Takeuchi,Taiichi Kyo,Kensuke Naito,H Sao,Masatomo Takahashi,S Miyawaki,Kazutaka Kuriyama,Shigeki Ohtake,Fumiharu Yagasaki,Hirokazu Murakami,Norio Asou,Ino T,Takahiro Okamoto,Noriko Usui,Miki Nishimura,Katsuji Shinagawa,T Fukushima,Hirokuni Taguchi,Takeshi Morii,Shuichi Mizuta,Hideki Akiyama,Y Nakamura,Ohshima T,Ryuzo Ohno +23 more
TL;DR: In order to improve the disappointing prognosis of adult patients with acute lymphoblastic leukemia, similar induction therapy as that used for acute myeloid leukemia (AML), ie frequent administration of doxorubicin (DOX), was applied, and Ph-negative chromosome was a common favorable prognostic factor for CR, longer OS and DFS.
Journal ArticleDOI
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Wen Jie Zhang,Kazunori Ohnishi,Kazuyuki Shigeno,Shinya Fujisawa,Kensuke Naito,Satoki Nakamura,Kaori Takeshita,Akihiro Takeshita,Ryuzo Ohno +8 more
TL;DR: Results showed that As 2O3 exerted variable and definite effects on lymphoid cells and indicated that As2O3 might be clinically useful in lymphoid neoplasms such as malignant lymphoma and CLL.
Journal ArticleDOI
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Kensuke Naito,Akihiro Takeshita,Kazuyuki Shigeno,Satoki Nakamura,Shinya Fujisawa,Kaori Shinjo,Hitoshi Yoshida,Kazunori Ohnishi,M Mori,Susumu Terakawa,Ryuzo Ohno +10 more
TL;DR: A dose-dependent, selective cytotoxic effect of CMA-676 was observed in cell lines that expressed CD33, and was dependent on the amount of CD33 and the proliferative speed of the cells.
Journal ArticleDOI
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Naohi Sahara,Akihiro Takeshita,Kazuyuki Shigeno,Shinya Fujisawa,Kaori Takeshita,Kensuke Naito,Michio Ihara,Takaaki Ono,Sadahiro Tamashima,Kenji Nara,Kazunori Ohnishi,Ryuzo Ohno +11 more
TL;DR: The higher incidence of plasmablastic cases suggested that CD56– MM may develop from a less mature plasma cell than CD56+ MM, which is associated with more aggressive disease.